Pfizer Inc stock (US7170811035): Q4 earnings show revenue growth but profit decline

Pfizer Inc, a leading global pharmaceutical company, continues to draw attention from US investors as its Indian affiliate Pfizer Limited released fourth quarter fiscal 2026 earnings on May 13, 2026. For the quarter ended March 31, 2026, sales rose 6.3% year-over-year to INR 6,292.3 million from INR 5,919.1 million, while revenue increased to INR 6,699.5 million from INR 6,364.9 million, according to Marketscreener as of May 13, 2026. Net income fell to INR 1,998.2 million from INR 3,309.4 million, with EPS dropping to INR 43.68 from INR 72.34.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Pfizer Inc: core business model

Pfizer Inc develops, manufactures and markets innovative medicines and vaccines worldwide. The company operates through a biopharmaceutical segment focused on primary care, specialty care and oncology products. Key brands include Comirnaty and Paxlovid from its COVID-19 portfolio, alongside ongoing investments in oncology and rare diseases. Pfizer's model emphasizes R&D spending, which stood at significant levels in recent years to fuel its pipeline of over 100 projects in clinical development.

With a presence in more than 185 countries, Pfizer generates substantial revenue from the US market, making it highly relevant for American retail investors. The company's scale allows it to navigate patent cliffs through acquisitions like Seagen in 2023, bolstering its oncology franchise.

Main revenue and product drivers for Pfizer Inc

Pfizer's revenue is driven by blockbuster drugs such as Eliquis for cardiovascular treatment, Prevnar for vaccines and Ibrance in oncology. In Q1 2026, Pfizer Inc held a 6.34% market share in its competitive segment, trailing Johnson & Johnson at 9.65%, per CSIMarket as of Q1 2026. Recent SEC filings highlight ongoing quarterly reporting, including a 10-Q on May 5, 2026.

Vaccines and antivirals remain pivotal, though post-pandemic normalization impacts growth. Pfizer Limited's Q4 results reflect regional dynamics in India, a key emerging market contributing to group diversification.

Industry trends and competitive position

The global pharmaceutical industry faces pressures from biosimilars, pricing regulations and innovation demands. Pfizer maintains a strong position through its $43 billion Seagen acquisition, enhancing antibody-drug conjugates. US investors benefit from Pfizer's NYSE listing and exposure to domestic healthcare spending, which accounts for nearly half of global pharma demand.

Why Pfizer Inc matters for US investors

As a NYSE-listed blue-chip stock, Pfizer offers US investors stability in the healthcare sector, with dividends yielding over 5% recently. Its role in US vaccine distribution and R&D tax credits underscore domestic relevance amid healthcare policy shifts.

Conclusion

Pfizer Inc demonstrates resilience with revenue growth in affiliate results, even as profits face headwinds. US investors monitor its pipeline and market share amid competitive pressures. Ongoing SEC disclosures provide transparency into operations.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.